Dynavax Technologies Corporation (NASDAQ:DVAX) Short Interest Down 14.0% in January

Dynavax Technologies Corporation (NASDAQ:DVAX) was the target of a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 9,129,174 shares, a drop of 14.0% from the December 31st total of 10,619,836 shares. Based on an average trading volume of 4,971,230 shares, the short-interest ratio is presently 1.8 days. Approximately 8.0% of the company’s shares are short sold. Approximately 8.0% of the company’s shares are short sold. Based on an average trading volume of 4,971,230 shares, the short-interest ratio is presently 1.8 days.

Dynavax Technologies Stock Down 0.1%

DVAX stock traded down $0.01 during midday trading on Tuesday, hitting $15.48. 3,434,323 shares of the company’s stock were exchanged, compared to its average volume of 3,319,223. The firm has a 50 day moving average price of $13.61 and a 200-day moving average price of $11.54. Dynavax Technologies has a 12-month low of $9.20 and a 12-month high of $15.73. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -41.84 and a beta of 0.97. The company has a current ratio of 7.62, a quick ratio of 6.94 and a debt-to-equity ratio of 0.41.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. The business had revenue of $94.88 million during the quarter, compared to the consensus estimate of $94.00 million. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. On average, analysts anticipate that Dynavax Technologies will post 0.32 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on DVAX shares. Wall Street Zen upgraded Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 27th. Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, January 21st. Finally, William Blair cut shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Dynavax Technologies presently has a consensus rating of “Hold” and an average target price of $24.33.

Insider Buying and Selling at Dynavax Technologies

In related news, COO David F. Novack sold 114,000 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $15.64, for a total transaction of $1,782,960.00. Following the completion of the sale, the chief operating officer directly owned 63,344 shares of the company’s stock, valued at approximately $990,700.16. This represents a 64.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.98% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in DVAX. State of Alaska Department of Revenue raised its position in shares of Dynavax Technologies by 1.2% during the 4th quarter. State of Alaska Department of Revenue now owns 57,170 shares of the biopharmaceutical company’s stock valued at $878,000 after acquiring an additional 667 shares in the last quarter. Profund Advisors LLC raised its holdings in shares of Dynavax Technologies by 2.7% during the third quarter. Profund Advisors LLC now owns 38,380 shares of the biopharmaceutical company’s stock worth $381,000 after purchasing an additional 995 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Dynavax Technologies by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,706 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 1,172 shares during the last quarter. Parkman Healthcare Partners LLC boosted its holdings in shares of Dynavax Technologies by 0.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 271,306 shares of the biopharmaceutical company’s stock valued at $2,694,000 after buying an additional 1,175 shares during the period. Finally, Osaic Holdings Inc. grew its position in shares of Dynavax Technologies by 15.1% during the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,226 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.